News & Analysis as of September 18, 2024

European Medicines Agency (EMA)

+ Follow

Steps Your Nonprofit Can Take to Mitigate Fraud Risks - Part 2
Why Retailers and Merchants Should Pay Attention to the CFPB - The Consumer Finance Podcast
The Justice Insiders Podcast - The Ever-Expanding Net: Corporate Compliance in an Era of Increasing Trade Sanctions and Restrictions
Fraud Risks at Nonprofit Organizations - Part 1
False Claims Act Insights - If Everything Matters, Nothing Does: Parsing Materiality in FCA Disputes
AGG Talks: Cross-Border Business Podcast - Episode 18: Navigating U.S. Sanctions and Their Implications for Non-U.S. Individuals and Entities
Navigating U.S. Sanctions and Their Implications for Non-U.S. Individuals and Entities
Power, Privacy, and Protection: Unpacking Security Challenges in the Energy Sector - Energy Law Insights
FCA Uncovered: Mitigating Risk in the Regulatory Spotlight — Regulatory Oversight Podcast
JONES DAY PRESENTS®: Cross-Border Trade Secret Litigation in the United States
Navigating Employment and Separation Agreements: Lessons From Al Pacino's Serpico — Hiring to Firing Podcast
What's the Tea in L&E? Love Contracts: Consensual Relationships in the Workplace
CMO Series EP131 - Noni Garratt-Wall of Charles Russell Speechlys on The Art Of A Law Firm Rebrand
Life After Love Gone Wrong Podcast: Season 3, Episode 4 - Splitting Costs: Forensic Accounting in Divorce
No Password Required: Chief Adversarial Officer at Secure Yeti, a DEF CON Groups Global Ambassador, and a World-Class Awkward Hugger
What to Do If the Government Knocks on Your Company’s Door … or Breaks It Down – Speaking of Litigation Podcast
Marketing Minute with NP Strategy (Video): How to Respond to a Cyber Security Breach
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 157: Sarah Glover, Maynard Nexsen Cybersecurity Attorney
ESG, DEI and Compliance
[Podcast] AI: The Next Big Thing in Government Contracting

The EMA intends to update the Guidance concerning Additional Risk Minimisation Measures

Hogan Lovells on 10/22/2020

The European Medicines Agency (“EMA”) has announced its intention to update the Agency’s existing guidance concerning additional risk minimisation measures (“aRMMs”). The revised version will provide extensive guidance on...more

EMA’s revised Guideline on first-in-human trials increases the level of protection of trial participants

Hogan Lovells on 7/28/2017

The European Medicines Agency (EMA) has released a new Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. The Guideline was adopted by...more

2 Results

View per page

Page: of 1

Risk Mitigation › European Union › European Medicines Agency (EMA)

The EMA intends to update the Guidance concerning Additional Risk Minimisation Measures

EMA’s revised Guideline on first-in-human trials increases the level of protection of trial participants

"My best business intelligence, in one easy email…"